Avadel Pharmaceuticals’ Research Pipeline
The Power Of Medicine. Reinvented.
Avadel’s proprietary drug delivery platforms - Micropump®, LiquiTime®, Trigger Lock™, and Medusa™ - allow for the optimization of a variety of pharmaceuticals across a wide range of indications. These technologies allow Avadel the potential to improve the way drugs are dosed and released throughout the system.
The company also selectively seeks approval from the U.S. Food and Drug Administration (FDA) for a number of commonly used pharmaceuticals that had not previously been approved. This strategy ensures patients are receiving products that are proven to be safe and effective. Bloxiverz®, Vaculep® and Akovaz™ are examples of previously unapproved pharmaceuticals, for which Avadel was first to gain approval.